GleamWall
中文EN

LONA LeonaBio, Inc.

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1620463 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-313.6%
TTM EPS YoY-129.8%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-729.0%
ROA-457.7%
ROIC (approx.)-3,861.7%
Asset turnover—

Leverage & solvency

Liabilities / assets58.0%
Debt / equity0.00x
Current ratio4.96x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.49x
Accruals ratio-234.3%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue——
R&D expense$17.50M$70.68M
SG&A expense$16.68M$26.09M
Operating income-$102.27M-$100.90M
Pretax income-$105.61M-$96.91M
Income tax$0—
Net income-$105.61M-$96.94M
EBITDA-$101.29M-$99.93M
EPS (basic)-24.70-25.19
EPS (diluted)-24.70-25.19
Weighted avg. shares (diluted)4.28M3.85M
Balance sheet
Cash & equivalents$69.28M$48.44M
Short-term investments$19.05M$2.84M
Current assets$89.46M$54.84M
PP&E, net$1.47M$2.44M
Total assets$92.15M$58.78M
Current liabilities$47.50M$13.13M
Total liabilities$64.36M$13.94M
Shareholders' equity$27.79M$44.84M
Shares outstanding9.34M3.90M
Cash flow statement
Operating cash flow-$45.73M-$97.17M
Capital expenditure—$33,000
Free cash flow—-$97.20M
Investing cash flow-$15.89M$54.83M
Financing cash flow$82.46M$194,000
Depreciation & amortization$972,000$970,000
Stock-based compensation$6.10M$11.05M

Free plan shows the latest 2 periods; Pro shows all 7 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.